BioSpace News Archive

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock.

Avalo Therapeutics, Inc. announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc.

Insmed Incorporated (Nasdaq: INSM) today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego.

Varex Imaging Corporation announced it has entered into a senior secured revolving credit agreement for an initial aggregate principal amount of up to $155 million.

Revance Therapeutics, Inc. announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units to 29 employees.

Inhibikase Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent developments.

Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it will be featured as a presenting company at the Emerging Growth Conference on April 3, 2024.

Abbott will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.

Linear Health Sciences announced the publication of a new whitepaper on accidental dislodgement of IV catheter lines.

Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced the appointment of Chris McDonald, Global Head of Technical Operations at Kite, a Gilead Company, to its Board of Directors.